Better Context → Better Decisions

Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.

Posted in: Autologous, CAR-T, CD19 Jul 22 | 2022CHMP Adopts Positive Opinion for Tecartus; Yescarta Absent From July’s CHMP Highlights Access Free Blast

Posted in: Autologous, BCMA, CAR-T Jul 21 | 2022UPDATE: Legend Discloses Carvykti's Q2 2022 Revenue of $24M Access Free Blast

Posted in: Autologous, CAR-T Jul 21 | 2022Are Cell Therapy Leaders Losing Their Innovative Edge? Final Analysis Access Free Blast

Posted in: Allogeneic, Autologous, CAR-T Jul 20 | 2022Are Cell Therapy Leaders Losing Their Innovative Edge? Spotlight on Gilead (Blast 6/6)Access Free Blast

Posted in: Autologous, BCMA, CAR-T, CD19 Jul 20 | 2022Kymriah’s Sales Remain Flat After US and EU Approvals in ≥3L FL, PHE885’s Submission Delayed to 2025; YTB323's Development Strategy Being Updated; Novartis Q2 2022 Earnings Call Summary Access Free Blast

Posted in: Autologous, BCMA, CAR-T, CD19 Jul 19 | 2022Gracell Appoints Samuel Zhang as Chief Business Officer Access Free Blast

Posted in: Autologous, BCMA, CAR-T Jul 19 | 2022No Carvykti Revenue Disclosed; JNJ Q2 2022 Earnings Call Summary Access Free Blast

Posted in: Allogeneic, Autologous, CAR-T, CD19 Jul 19 | 2022Are Cell Therapy Leaders Losing Their Innovative Edge? Spotlight on Gilead (Blast 5/6)Access Free Blast

Posted in: Autologous, CAR-T, CD19 Jul 18 | 2022Type II Variations for Yescarta and Tecartus Listed in July’s CHMP Agenda Access Free Blast

Posted in: Autologous, CAR-T, CD19 Jul 15 | 2022New Yescarta Ph2 Trial (ZUMA-24) for 2L LBCL in the Outpatient Setting Posted Access Free Blast

Posted in: Allogeneic, Autologous, CAR-T, CD19, TCR Jul 15 | 2022Are Cell Therapy Leaders Losing Their Innovative Edge? Spotlight on BMS (Blast 4/6)Access Free Blast

Posted in: Allogeneic, Autologous, BCMA, CAR-T Jul 14 | 2022Are Cell Therapy Leaders Losing Their Innovative Edge? Spotlight on BMS (Blast 3/6)Access Free Blast

Posted in: Autologous, CAR-T, CD19 Jul 13 | 2022Breyanzi Included in the NCCN Guidelines for the Treatment of 2L DLBCL Access Free Blast

Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Jul 13 | 2022Are Cell Therapy Leaders Losing Their Innovative Edge? Spotlight on Novartis (Blast 2/6)Access Free Blast

Posted in: Allogeneic, Autologous, CAR-T, CD19 Jul 12 | 2022Are Cell Therapy Leaders Losing Their Innovative Edge? Spotlight on Novartis (Blast 1/6)Access Free Blast

Posted in: Autologous, CAR-T Jul 08 | 2022Are Cell Therapy Leaders Losing Their Innovative Edge? Spotlight Series on Novartis, BMS, and Gilead (Kite)Access Free Blast

Posted in: Autologous, CAR-T, CD19 Jul 05 | 2022UPDATED: Indications Table for CD19 CAR-T US Approvals and Submissions Access Free Blast

Posted in: Autologous, CAR-T, CD19 Jun 29 | 2022Thoughts on Breyanzi’s FDA Approval in 2L LBCL Access Free Blast

Posted in: Autologous, CAR-T, CD19 Jun 28 | 2022The EC Grants Yescarta Marketing Authorization for ≥4L R/R FL Access Free Blast

Posted in: Autologous, CAR-T, CD19 Jun 24 | 2022Breyanzi Receives FDA Approval for 2L LBCL Access Free Blast

« prev 1 … 13 14 15 16 17 … 32 next »

Get the Latest Analysis

Stay informed and aligned with frequent updates to keep a pulse on the industry.

If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.

Contact UsLog In

error: Content is protected !!